Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Seres Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 120 | 124 | +4 |
| Shares | 104.7M | 105.1M | +343.2K (+0.3%) |
| Value | $671.6M | $588.2M | −$83.4M (−12.4%) |
New holders (21)
Institutions that held Seres Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jennison Associates LLC | 668,441 | $3.74M | 0.00% |
| Millennium Management LLC | 205,472 | $1.15M | 0.00% |
| Mackenzie Financial Corp | 78,050 | $437.1K | 0.00% |
| Jump Financial, LLC | 73,134 | $409.6K | 0.02% |
| Ergoteles LLC | 47,685 | $267.0K | 0.01% |
| Jane Street Group, LLC | 44,789 | $250.8K | 0.00% |
| ExodusPoint Capital Management, LP | 43,204 | $242.0K | 0.00% |
| Boulder Hill Capital Management LP | 20,200 | $113.1K | 0.09% |
| Wedbush Securities Inc | 19,874 | $111.0K | 0.01% |
| Pictet Asset Management SA | 13,692 | $77.0K | 0.00% |
| Two Sigma Securities, LLC | 11,147 | $62.4K | 0.01% |
| Point72 Middle East FZE | 10,812 | $60.5K | 0.00% |
| Bridgefront Capital, LLC | 10,359 | $58.0K | 0.04% |
| Walleye Capital LLC | 8,162 | $45.7K | 0.00% |
| Simplex Trading, LLC | 4,943 | $27.0K | 0.00% |
| Walleye Trading LLC | 1,357 | $7.60K | 0.00% |
| TCI Wealth Advisors, Inc. | 544 | $3.05K | 0.00% |
| McElhenny Sheffield Capital Management, LLC | 102 | $571 | 0.00% |
| Grey Fox Wealth Advisors, LLC | 100 | $560 | 0.00% |
| Belpointe Asset Management LLC | 49 | $274 | 0.00% |
| Sofos Investments, Inc. | 6 | $56 | 0.00% |
Sold out (17)
Institutions that held Seres Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AQR Capital Management LLC | 253,919 | $1.63M |
| Panagora Asset Management Inc | 167,089 | $1.07M |
| Ikarian Capital, LLC | 131,310 | $843.0K |
| ClariVest Asset Management LLC | 117,387 | $753.0K |
| Graham Capital Management, L.P. | 106,134 | $681.0K |
| STRS Ohio | 93,700 | $601.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 70,085 | $450.0K |
| Alps Advisors Inc | 67,770 | $435.0K |
| Susquehanna Fundamental Investments, LLC | 52,988 | $340.0K |
| Parallax Volatility Advisers, L.P. | 45,986 | $295.0K |
| Caxton Associates LP | 42,166 | $271.0K |
| Ensign Peak Advisors, Inc | 30,780 | $198.0K |
| Algert Global LLC | 21,642 | $139.0K |
| Raymond James & Associates | 20,330 | $131.0K |
| Cipher Capital LP | 15,271 | $98.0K |
| Boothbay Fund Management, LLC | 13,937 | $89.0K |
| Macquarie Group Ltd | 0 | $15.0K |